Quantcast

Novartis’s Alcon introduces new innovations in cataract surgery at ESCRS 2017 annual congress

Alcon, a division of Novartis, will introduce Clareon, the intraocular lens (IOL) with the most advanced optic material available in an automated, disposable, pre-loaded delivery system, at the XXXV European Society of Cataract & Refractive Surgeons (ESCRS) congress taking place October 7 – 11 in Lisbon, Portugal.

Read more

FDA OK’s Eli Lilly’s breast cancer drug

The U.S. Food and Drug Administration has approved  Eli Lilly’s Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy).

Read more

Novartis and UC Berkeley collaborate to tackle ‘undruggable’ disease targets

Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered “undruggable.”

Read more